* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
CAI:RMDA's PEG Ratio is ranked better than 74.5% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.75
vs CAI:RMDA: 0.86
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PEG Ratio Related Terms
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PEG Ratio Chart
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PEG Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a PEG Ratio of 0.86 as of Jul. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 37% above median its historical median of 0.63. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' PEG Ratio has ranged from 0.45 to 1.01. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #89 out of 349 companies in the Drug Manufacturers industry, placing it in the top 25.5%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' PEG Ratio too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current PEG Ratio of 0.86 is 37% above median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 1.01. The Drug Manufacturers industry median PEG Ratio is 1.75. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 0.86 is 50.9% below this industry median. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #89 out of 349 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #89 out of 349 companies for PEG Ratio. This puts Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the upper half of its industry. The industry median PEG Ratio is 1.75. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 0.86 is 50.9% below this benchmark. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own PEG Ratio has ranged from 0.45 to 1.01 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 1.75, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.75, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current PEG Ratio of 0.86 is 50.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current PEG Ratio is 0.86, which is 37% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.08, compared to a current price of E£5.10 — trading 25% above its estimated fair value. The current PEG Ratio is 0.86, which is 37% above median its 10-year median of 0.63 and 50.9% below the Drug Manufacturers industry median of 1.75. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current PEG Ratio is 0.86 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.
Key valuation signals for CAI:RMDA:
PEG Ratio: 0.86 (37% above median its 10-year median of 0.63)
GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
Industry Position: 50.9% below the Drug Manufacturers median (#89 of 349)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score
Get the complete analysis for CAI:RMDA
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
